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| INTRODUC TI ON
In select patients, islet cell transplantation has become an attractive clinical therapy to restore glycemic control and ameliorate the secondary complications associated with type 1 diabetes.
1 The
Edmonton protocol reported by Shapiro and colleagues in 2000 was the first to achieve sustainable insulin independence up to 1 year post-islet transplantation in 7 consecutive patients, owing, in part, to more potent immunosuppressive drugs, the avoidance of corticosteroids, as well as higher-quality islet preparations. 2 Despite initial successes, 5-year follow-up revealed that insulin independence was not durable, as most patients returned to moderate exogenous insulin administration, albeit with 80% of patients maintaining Cpeptide. 3 Within recent years, inroads in clinical islet transplantation have improved long-term transplantation outcomes, including but not limited to the introduction of selective and potent therapeutic agents in the initiation and maintenance of immunosuppression.
4
Improvements in clinical islet transplantation have translated into 5-year insulin independence rates matching that of whole pancreas transplantation. 5 However, the sustainability of insulin independence in most patients requires multiple islet infusions, with single-donor islet transplant success rates being accomplished at few centers worldwide. 6 Results from a recent multicenter, singlearm phase 3 study completed by the Clinical Islet Transplant Consortium revealed 87.5% and 71% of participants at 1-year and 2-year follow-ups, respectively, exhibited restoration of glycemic control and hypoglycemic awareness when receiving 1 or 2 islet infusions. 7 Considerable evidence suggests that islet function and viability can be compromised during organ procurement, islet isolation, and culture, thus contributing to islet cell death and consequently compromising long-term engraftment outcomes. [8] [9] [10] The events contributing to cellular death during procurement and isolation have been attributed, at least in part, to oxidative stress, the imbalance between free radical production, and antioxidant availability. 11 Compared with other tissues within the body, islets exhibit reduced inherent antioxidant expression, including manganese superoxide dismutase (MnSOD). 12, 13 As such, islets are considerably susceptible to the deleterious events associated with oxidative stress, including impaired β cell metabolic function and islet loss.
11
Accordingly, strategies to augment endogenous antioxidant expression by using therapeutic agents have been undertaken to mitigate events associated with oxidative stress, thus promoting islet survivability and engraftment. Recent strategies have included natural antioxidants, such as red ginseng and anthocyanin, to improve islet viability in vitro, as well as to improve engraftment in rodent transplant models. 14, 15 Alternatively, the efficacy of low-molecularweight, metalloporphyrin MnSOD mimics have gained considerable interest due to their ability to dismutate superoxide with a high rate constant. 16, 17 Previous studies evaluating early-generation metalloporphyrin MnSOD mimics demonstrated an inhibition of nuclear factor-κB activation and preservation of islet mass in vivo in diabetic mice. 11, 18, 19 However, the translation of early-generation MnSODs in islet isolation and transplantation has yet to confer significant benefit in the clinical setting. 20 Subsequent generation of a newly
, has demonstrated the ability to reduce the generation of reactive oxygen species (ROS) in a murine donation after circulatory death islet transplantation model, thus supporting further investigation of MnSODs in islet isolation and transplantation preclinical models. 21 Here, we examined whether the administration of a novel, redoxactive metalloporphyrin, BMX-001, could confer greater cytoprotection than the earlier-generation MnSOD, BMX-010, in human islets. We also evaluated whether the administration of BMX-001 during organ procurement and islet culture could preserve in vitro islet function and subsequent engraftment outcomes in a syngeneic, marginal murine transplant model. We further evaluated whether human islets supplemented with BMX-001 could improve engraftment outcomes in an immunocompromised murine transplant model.
| MATERIAL S AND ME THODS

| BMX-010 and BMX-001
The metalloporphyrin SOD mimetics BMX-010 and BMX-001 were obtained from BioMimetix Inc. (Denver, CO). A stock preparation of 1 mmol/L BMX-010 and BMX-001 was prepared by dissolving each drug in PBS. 
| Human islet culture and in vitro assessment
| Mouse islet isolation
Pancreatic islets were isolated from 8-to 12-week-old male BALB/c mice (Jackson Laboratories, Bar Harbor, ME, USA 
| Mouse islet yield and culture
Immediately postisolation, islets from each group were harvested to determine islet yield. Islet isolation yield is expressed as total number of islets isolated per pancreas (islets/pancreas). Immediately postisolation, islets were either assessed for in vitro viability and function or cultured for 24 hours at 37°C/5% CO 2 in standard CMRL-1066 medium supplemented with 10% fetal bovine serum, l-glutamine 
| Murine islet insulin secretion assessment
| Apoptosis analysis
For murine islets, apoptosis was assessed between treatment groups in islets harvested 24 hours postculture. For human islets, apoptosis was assessed between groups in islets harvested 24 hours and 7 days postculture. Apoptosis was assayed in all islets groups by using terminal deoxynucleotidyl transferase dUTP nick end labeling 
| Percent islet recovery
For murine studies, subsequent to 24-hour culture, islets were harvested and counted to determine islet recovery postculture.
For human islet studies, islets were harvested 7 days postculture.
Percent islet recovery was determined as the ratio of total islets harvested 24 hours postculture relative to the number of islets harvested immediately postisolation.
| Membrane integrity
Mouse islet viability was assessed immediately after isolation and 24 hours postculture for control and 10-and 34-μmol/L BMX-001-supplemented islets. Human islets were harvested 7 days postculture, and membrane integrity was assessed 7 days postculture. Simultaneous staining of live and dead cells using a membrane integrity fluorescence assay (SytoGreen 13 and ethidium bromide;
Invitrogen, Carlsbad, CA, USA) was used to determine islet viability.
The percentage of viable cells is expressed for each sample on the day of isolation (D 0 ) and 24 hours postculture (D 1 ).
| Diabetes induction and islet transplantation
One 
| Evaluation of islet graft function
Nonfasting blood glucose measurements (in mmol/L) were assessed 3 times weekly by using a portable glucometer (FreeStyle InsuLinx;
Abbott Diabetes Care Ltd., Oxon, UK) in the 3 transplant groups tested. Graft function and reversal of diabetes were defined as 2 consecutive readings of ≤11.1 mmol/L and were maintained until study completion. Intraperitoneal glucose tolerance tests (IPGTTs)
were conducted 60 days posttransplantation in all islet transplant recipients. At the time of study completion, islet-bearing kidney grafts were retrieved via recovery nephrectomy. For euglycemic recipients, nonfasting blood glucose measurements were monitored up to 7 days subsequent to graft removal to confirm a return to hyperglycemia. Details regarding IPGTT assessment are described further in Supporting Information.
| Proinflammatory assessment and caspase-3 activation
Mouse islet-bearing kidney grafts (3 recipients per group receiving 150 islets each) were harvested 24 hours posttransplantation to determine proinflammatory cytokine concentrations and cleaved caspase-3 activation. Details regarding graft assessment are described in Supporting Information.
| Statistical analysis
Mean insulin secretion, glucose stimulation index, nonfasting daily blood glucose, IPGTT blood glucose responses, blood glucose area under the curve (AUC), and percent apoptosis data are represented as mean ± SEM values. Comparison between mean absolute insulin secretion in low and high glucose within groups was conducted by using paired Student t-test.
The difference between mean stimulation index values was conducted with 1-way ANOVA. Tukey post-hoc tests were used after the ANOVAs for multiple comparisons between study groups. Kaplan-Meyer survival function curves were compared by using the log-rank statistical method (Mantel-Cox). P < .05 was considered significant.
| RE SULTS
| BMX-001, but not BMX-010, reduces apoptosis in human islets cultured for 7 days
To determine the cytoprotective effects of BMX-010 and/or BMX- 55.8% ± 9.2%, P > .05, 1-way ANOVA) ( Figure 1E ). Islets cultured in the presence of 10 μmol/L BMX-001 exhibited no significant difference relative to nontreated control islets (9.9% ± 1.4%) (P > .05, 1-way ANOVA) but were significantly higher than 34 μmol/L BMX-001-treated islets (P < .05, 1-way ANOVA). per pancreas were achieved, respectively (P > .05) ( Figure S2A ).
| Mouse islets
| Isolation and culture with BMX-001 is nontoxic to mouse islets
When harvested 24 hours postculture, percent islet recovery for control islets cultured in standard media (71.1% ± 11.4%) was comparable to islets cultured in media supplemented with 10 μmol/L BMX-001 (68.9% ± 17%). Islet recovery for 34 μmol/L BMX-001-cultured islets exhibited a trend toward increased percent recovery relative to control (88.8% ± 3.4%) (P > .05) ( Figure S2B ). Islet 
| Glucose tolerance testing
| Evaluation of long-term human islet engraftment
To further evaluate whether BMX-001 could improve engraftment outcomes with human islets supplemented with or without BMX-001 in immunocompromised mice, recipients were transplanted with a marginal transplant dose of 750 IE under the KC. The average human islet purity for the transplant preparations used in this study was 48.8% (n = 5 pancreata). Euglycemia was achieved in 8 
| D ISCUSS I ON
Endogenous antioxidant systems play a critical role in the redox modulation of free radicals. The imbalance between the generation of free radicals and native antioxidant expression, favoring the former, results in cytotoxic oxidative stress. Due to their inherently reduced expression of antioxidants, such as superoxide dismutase, catalase, and glutathione peroxidase, islets have increased susceptibility to the deleterious events associated with oxidative stress. [25] [26] [27] [28] Islets experience various stresses during isolation and culture that result in cellular redox imbalance and subsequent cell death.
29
Incorporation of soluble reagents capable of increasing islet antioxidant defenses to ameliorate the consequences of oxidative stress, including the generation of ROS, have been shown to have positive effects on islet survival and engraftment. 27 Early-generation metalloporphyrin MnSOD mimics have also been introduced in experimental islet transplantation as a means to abrogate these injurious events, promote survivability, and augment islet engraftment. 19, 26 In the current study, we first investigated whether long-term culture of human islets in the presence of metalloporphyrin MnSOD mimics BMX-010 or BMX-001 could confer cytoprotection in vitro.
At the time of assessment, BMX-010 was under clinical investigation, and the development of the next-generation MnSOD mimic, BMX-001, was made available with little preclinical efficacy evaluation. We used a dose of both drugs that mimics endogenous physiological SOD levels expressed in islets (34 μmol/L), which revealed long-term islets cultured in BMX-001 exhibited reduced TUNEL relative to control islets, while no discernible difference was observed between control and BMX-010-treated human islets.
Given that BMX-001 conferred significant cytoprotection relative to BMX-010 in preclinical long-term human islet culture, we prospective application in the clinical setting, the compound was introduced during murine pancreas enzymatic distention, digestion, cold storage, and culture media supplementation but was not delivered to transplant recipients. 20 Administration of either BMX-001 dose during islet isolation and culture did not alter yield or recovery 24 hours postculture, respectively, or affect islet viability as assessed by membrane integrity.
While no additional benefit was conferred, these results demonstrate that the drug is nontoxic at the prescribed doses, thus encouraging its use in the clinical setting.
Conversely, our results demonstrate that of the doses tested, 34 μmol/L BMX-001 exhibited improved islet function and viability relative to nontreated control murine islets cultured for 24 hours.
Our previous study using BMX-001 in a murine islet isolation and culture model revealed that this agent is capable of minimizing the generation of ROS as exhibited by a significant reduction in extracellular ROS, which may account for improved islet viability. 
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